1,008
Participants
Start Date
January 31, 2005
Primary Completion Date
April 30, 2012
Study Completion Date
March 31, 2013
Interferon beta 1-a
The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
glatiramer acetate
The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
placebo
an inactive substance
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
Neuro Associates of Albany, PC, Albany
University of Miami - Neurology, Miami
Neurology Specialists, Dayton
Northwest Neurospecialists PLLC, Tucson
University of California - Davis Medical Center, Sacramento
University of Alabama - Birmingham, Birmingham
Barrow Neurology Clinic, Phoenix
Mayo Clinic - Scottsdale, Scottsdale
Sutter East Bay Medical Group, Berkeley
Neurology Center North Orange County, La Habra
VA West Los Angeles Healthcare Center, Los Angeles
Alpine Clinical Research Center, Boulder
Patricia Fodor P.C., Colorado Springs
University of Colorado Health Sciences Center, Denver
Yale University School of Medicine, New Haven
Neurology Associates, PA, Maitland
MS Center of Atlanta, Atlanta
Shepherd Center, Atlanta
Northwest University, Chicago
Consultants in Neurology - Multiple Sclerosis Center, Northbrook
University of Illinois College of Medicine, Peoria
Ruan Neurology Clinic and Research Center, Des Moines
University of Kansas Medical Center, Kansas City
Maryland Center for MS, Baltimore
Tufts-New England Medical Center, Boston
University of Massachusetts Memorial Medical Center, Boston
Lahey Clinic, Burlington
Wayne State University, Detroit
Michigan State University, East Lansing
Minneapolis Clinic - MS Center, Golden Valley
Mayo Clinic - Rochester, Rochester
St. Louis University - St. Louis VA, St Louis
Washington University School of Medicine, St Louis
Northern Rockies MS Center, Billings
Dartmouth Medical School, Lebanon
CentraState Medical Center, Freehold
University of New Mexico, Albuquerque
Albany Medical College, Albany
The Jacobs Neurological Institute, Buffalo
Winthrop Neurology Faculty Practice, Mineola
NYU Hospital For Joint Diseases, New York
South Shore Neurologic Associates Inc., Patchogue
University of Rochester, Rochester
SUNY Upstate Medical University, Syracuse
CMC-Neuroscience & Spine Institute, Division of Neurology, MS Center, Charlotte
Meritcare Neuroscience, Fargo
NeuroCare Center, Inc., Canton
Cleveland Clinic, Cleveland
Ohio State University, Columbus
Medical College Of Ohio, Toledo
Oak Clinic for Multiple Sclerosis, Uniontown
University of Pennsylvania, Philadelphia
Allegheny MS Treatment Center, Pittsburgh
Vanderbilt University Medical Center, Nashville
Baylor College of Medicine, Houston
University of Texas - Houston, Houston
University of Utah, Salt Lake City
Neurological Research Center, Inc., Bennington
Fletcher Allen Health Care, Burlington
Neurological Associates, Inc., Richmond
Virginia Commonwealth University, Richmond
MS Center at Evergreen, Seattle
Virginia Mason Medical Center, Seattle
Marshfield Clinic, Marshfield
Regional MS Center at St. Luke's Medical Center, Milwaukee
Foothills Medical Centre, Calgary
Capital Health and the University of Alberta, Edmonton
Ottawa Hospital, Ottawa
St. Michael's Hospital-Multiple Sclerosis Research Center, Toronto
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Fred Lublin
OTHER